-
1
-
-
3042530369
-
Iron in normal and pathological brain
-
Elsevier. Amsterdam/New York. In press
-
YOUDIM, M.B.H. & P. RIEDERER. 2004. Iron in normal and pathological brain. In Encyclopedia of Neuroscience. Elsevier. Amsterdam/New York. In press.
-
(2004)
Encyclopedia of Neuroscience
-
-
Youdim, M.B.H.1
Riederer, P.2
-
2
-
-
0025963530
-
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains
-
SOFIC, E. et al. 1991. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56: 978-982.
-
(1991)
J. Neurochem.
, vol.56
, pp. 978-982
-
-
Sofic, E.1
-
3
-
-
0024557734
-
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
-
RIEDERER, P. et al. 1989. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52: 515-520.
-
(1989)
J. Neurochem.
, vol.52
, pp. 515-520
-
-
Riederer, P.1
-
4
-
-
84996111069
-
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
-
YOUDIM, M.B.H., D. BEN-SHACHAR & P. RIEDERER. 1989. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. Suppl. 126: 47-54.
-
(1989)
Acta Neurol. Scand. Suppl.
, vol.126
, pp. 47-54
-
-
Youdim, M.B.H.1
Ben-Shachar, D.2
Riederer, P.3
-
5
-
-
0036798434
-
Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease
-
FAUCHEUX, B.A. et al. 2002. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83: 320-330.
-
(2002)
J. Neurochem.
, vol.83
, pp. 320-330
-
-
Faucheux, B.A.1
-
6
-
-
0024356620
-
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
-
DEXTER, D.T. et al. 1989. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52: 1830-1836.
-
(1989)
J. Neurochem.
, vol.52
, pp. 1830-1836
-
-
Dexter, D.T.1
-
7
-
-
0024585155
-
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
-
DEXTER, D.T. et al. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52: 381-389.
-
(1989)
J. Neurochem.
, vol.52
, pp. 381-389
-
-
Dexter, D.T.1
-
8
-
-
0025606922
-
Brain iron and ferritin in Parkinson's and Alzheimer's diseases
-
JELLINGER, K. et al. 1990. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Parkinson's Dis. Dementia Sect. 2: 327-340.
-
(1990)
J. Neural Transm. Parkinson's Dis. Dementia Sect.
, vol.2
, pp. 327-340
-
-
Jellinger, K.1
-
9
-
-
0026666528
-
Iron-melanin complex in substantia nigra of parkinsonian brains: An X-ray microanalysis
-
JELLINGER, K. et al. 1992. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59: 1168-1171.
-
(1992)
J. Neurochem.
, vol.59
, pp. 1168-1171
-
-
Jellinger, K.1
-
10
-
-
0032975570
-
The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease
-
JELLINGER, K.A. 1999. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140.
-
(1999)
Drugs Aging
, vol.14
, pp. 115-140
-
-
Jellinger, K.A.1
-
11
-
-
0028000825
-
Altered brain metabolism of iron as a cause of neurodegenerative diseases?
-
GERLACH, M. et al. 1994. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 793: 793-807.
-
(1994)
J. Neurochem.
, vol.793
, pp. 793-807
-
-
Gerlach, M.1
-
12
-
-
0034796353
-
Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment
-
HALLIWELL, B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716.
-
(2001)
Drugs Aging
, vol.18
, pp. 685-716
-
-
Halliwell, B.1
-
13
-
-
0026034279
-
Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An X-ray microanalysis
-
HIRSCH, E.C. et al. 1991. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56: 446-451.
-
(1991)
J. Neurochem.
, vol.56
, pp. 446-451
-
-
Hirsch, E.C.1
-
14
-
-
0026662141
-
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
-
KASTNER, A. et al. 1992. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59: 1080-1089.
-
(1992)
J. Neurochem.
, vol.59
, pp. 1080-1089
-
-
Kastner, A.1
-
15
-
-
0035043251
-
Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP)
-
TAKANASHI, M. et al. 2001. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinson's Relat. Disord. 7: 311-314.
-
(2001)
Parkinson's Relat. Disord.
, vol.7
, pp. 311-314
-
-
Takanashi, M.1
-
16
-
-
0000594895
-
Brain iron metabolism: Biochemical and behavioral aspects in relation to dopaminergic neurotransmission
-
Plenum. New York
-
YOUDIM, M.B.H. 1985. Brain iron metabolism: biochemical and behavioral aspects in relation to dopaminergic neurotransmission. In Handbook of Neurochemistry. Plenum. New York.
-
(1985)
Handbook of Neurochemistry
-
-
Youdim, M.B.H.1
-
17
-
-
0026337175
-
Oxidative stress as a cause of Parkinson's disease
-
JENNER, P. 1991. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136: 6-15.
-
(1991)
Acta Neurol. Scand. Suppl.
, vol.136
, pp. 6-15
-
-
Jenner, P.1
-
18
-
-
0029751104
-
Oxidative stress and the pathogenesis of Parkinson's disease
-
JENNER, P. & C.W. OLANOW. 1996. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-S170.
-
(1996)
Neurology
, vol.47
-
-
Jenner, P.1
Olanow, C.W.2
-
19
-
-
0034079858
-
Oxidative stress, mitochondrial respiration, and Parkinson's disease
-
COHEN, G. 2000. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann. N.Y. Acad. Sci. 899: 112-120.
-
(2000)
Ann. N.Y. Acad. Sci.
, vol.899
, pp. 112-120
-
-
Cohen, G.1
-
20
-
-
0026733994
-
MR1, brain iron, and experimental Parkinson's disease
-
HALL, S., J.N. RUTLEDGE & T. SCHALLERT. 1992. MR1, brain iron, and experimental Parkinson's disease. J. Neurol. Sci. 113: 198-208.
-
(1992)
J. Neurol. Sci.
, vol.113
, pp. 198-208
-
-
Hall, S.1
Rutledge, J.N.2
Schallert, T.3
-
21
-
-
0027991538
-
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: A histochemical and neurochemical study
-
OESTREICHER, E. et al. 1994. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660: 8-18.
-
(1994)
Brain Res.
, vol.660
, pp. 8-18
-
-
Oestreicher, E.1
-
22
-
-
0028045734
-
Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: Evidence from proton microprobe elemental microanalysis
-
TEMLETT, J.A. et al. 1994. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62: 134-146.
-
(1994)
J. Neurochem.
, vol.62
, pp. 134-146
-
-
Temlett, J.A.1
-
23
-
-
0028266425
-
Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys
-
MOCHIZUKI, H. et al. 1994. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168: 251-253.
-
(1994)
Neurosci. Lett.
, vol.168
, pp. 251-253
-
-
Mochizuki, H.1
-
24
-
-
0029662001
-
An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys
-
GOTO, K. et al. 1996. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res. 724: 125-128.
-
(1996)
Brain Res.
, vol.724
, pp. 125-128
-
-
Goto, K.1
-
25
-
-
3042530369
-
Iron in the brain, normal and pathological
-
Elsevier. Amsterdam/New York
-
YOUDIM, M.B.H. & P. RIEDERER. 2002. Iron in the brain, normal and pathological. In Encyclopedia of Neuroscience. Elsevier. Amsterdam/New York.
-
(2002)
Encyclopedia of Neuroscience
-
-
Youdim, M.B.H.1
Riederer, P.2
-
26
-
-
0036710567
-
Glutathione, iron, and Parkinson's disease
-
BHARATH, S. et al. 2002. Glutathione, iron, and Parkinson's disease. Biochem. Pharmacol. 64: 1037-1048.
-
(2002)
Biochem. Pharmacol.
, vol.64
, pp. 1037-1048
-
-
Bharath, S.1
-
27
-
-
0024805708
-
Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain
-
PERUMAL, A.S. et al. 1989. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res. 504: 139-141.
-
(1989)
Brain Res.
, vol.504
, pp. 139-141
-
-
Perumal, A.S.1
-
28
-
-
0028916715
-
Free radical-generated neurotoxicity of 6-hydroxydopamine
-
KUMAR, R., A.K. AGARWAL & P.K. SETH. 1995. Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 64: 1703-1707.
-
(1995)
J. Neurochem.
, vol.64
, pp. 1703-1707
-
-
Kumar, R.1
Agarwal, A.K.2
Seth, P.K.3
-
29
-
-
0022650447
-
Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment
-
YONG, V.W., T.L. PERRY & A.A. KRISMAN. 1986. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63: 56-60.
-
(1986)
Neurosci. Lett.
, vol.63
, pp. 56-60
-
-
Yong, V.W.1
Perry, T.L.2
Krisman, A.A.3
-
30
-
-
0035085603
-
Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
-
GRUNBLATT, E. et al. 2001. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77: 146-156.
-
(2001)
J. Neurochem.
, vol.77
, pp. 146-156
-
-
Grunblatt, E.1
-
31
-
-
0034941949
-
Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray
-
GRUNBLATT, E. et al. 2001. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J. Neurochem. 78: 1-12.
-
(2001)
J. Neurochem.
, vol.78
, pp. 1-12
-
-
Grunblatt, E.1
-
32
-
-
0024368622
-
6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation
-
MONTEIRO, H.P. & C.C. WINTERBOURN. 1989. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38: 4177-4182.
-
(1989)
Biochem. Pharmacol.
, vol.38
, pp. 4177-4182
-
-
Monteiro, H.P.1
Winterbourn, C.C.2
-
33
-
-
0025677734
-
Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions
-
LODE, H.N. et al. 1990. Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Radical Res. Commun. 11: 153-158.
-
(1990)
Free Radical Res. Commun.
, vol.11
, pp. 153-158
-
-
Lode, H.N.1
-
34
-
-
0030598917
-
Dopamine, 6-hydroxydopamine, iron, and dioxygen - Their mutual interactions and possible implication in the development of Parkinson's disease
-
LINERT, W. et al. 1996. Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta 1316: 160-168.
-
(1996)
Biochim. Biophys. Acta
, vol.1316
, pp. 160-168
-
-
Linert, W.1
-
35
-
-
0034724378
-
Interaction between 6-hydroxydopamine and transferrin: "let my iron go"
-
BORISENKO, G.G. et al. 2000. Interaction between 6-hydroxydopamine and transferrin: "let my iron go". Biochemistry 39: 3392-3400.
-
(2000)
Biochemistry
, vol.39
, pp. 3392-3400
-
-
Borisenko, G.G.1
-
36
-
-
0030790785
-
Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease
-
PEZZELLA, A. et al. 1997. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 40: 2211-2216.
-
(1997)
J. Med. Chem.
, vol.40
, pp. 2211-2216
-
-
Pezzella, A.1
-
37
-
-
0001204988
-
Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: Potential implications to Parkinson's disease
-
HAN, J. et al. 1999. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J. Neurochem. 73: 1683-1695.
-
(1999)
J. Neurochem.
, vol.73
, pp. 1683-1695
-
-
Han, J.1
-
38
-
-
0024500857
-
Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence
-
CADET, J.L. et al. 1989. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476: 10-15.
-
(1989)
Brain Res.
, vol.476
, pp. 10-15
-
-
Cadet, J.L.1
-
39
-
-
0030606143
-
Melatonin is protective against MPTP-induced striatal and hippocampal lesions
-
ACUNA-CASTROVIEJO, D. et al. 1997. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60: L23-L29.
-
(1997)
Life Sci.
, vol.60
-
-
Acuna-Castroviejo, D.1
-
40
-
-
0030592141
-
Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction
-
GASSEN, M. et al. 1996. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308: 219-225.
-
(1996)
Eur. J. Pharmacol.
, vol.308
, pp. 219-225
-
-
Gassen, M.1
-
42
-
-
0030864433
-
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
-
Budapest
-
LAN, J. & D.H. JIANG. 1997. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural Transm. (Budapest) 104: 469-481.
-
(1997)
J. Neural Transm.
, vol.104
, pp. 469-481
-
-
Lan, J.1
Jiang, D.H.2
-
43
-
-
0030666415
-
Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease
-
LAN, J. & D.H. JIANG. 1997. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural Transm. 104: 649-660.
-
(1997)
J. Neural Transm.
, vol.104
, pp. 649-660
-
-
Lan, J.1
Jiang, D.H.2
-
44
-
-
0034851553
-
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration
-
LEVITES, Y. et al. 2001. Green tea polyphenol (-)-epigallocatechin-3- gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78: 1073-1082.
-
(2001)
J. Neurochem.
, vol.78
, pp. 1073-1082
-
-
Levites, Y.1
-
45
-
-
0033669158
-
The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease
-
MOUSSAOUI, S. et al. 2000. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166: 235-245.
-
(2000)
Exp. Neurol.
, vol.166
, pp. 235-245
-
-
Moussaoui, S.1
-
46
-
-
0035895844
-
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: Behavioral and histochemical evidence
-
ROGHANI, M. & G. BEHZADI. 2001. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. 892: 211-217.
-
(2001)
Brain Res.
, vol.892
, pp. 211-217
-
-
Roghani, M.1
Behzadi, G.2
-
47
-
-
0025980955
-
The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine- induced degeneration of nigrostriatal dopamine neurons
-
BEN-SHACHAR, D. et al. 1991. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56: 1441-1444.
-
(1991)
J. Neurochem.
, vol.56
, pp. 1441-1444
-
-
Ben-Shachar, D.1
-
48
-
-
0242684415
-
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease
-
KAUR, D. et al. 2003. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909.
-
(2003)
Neuron
, vol.37
, pp. 899-909
-
-
Kaur, D.1
-
49
-
-
0025824668
-
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats
-
BEN-SHACHAR, D. & M.B. YOUDIM. 1991. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J. Neurochem. 57: 2133-2135.
-
(1991)
J. Neurochem.
, vol.57
, pp. 2133-2135
-
-
Ben-Shachar, D.1
Youdim, M.B.2
-
50
-
-
0014376793
-
6-Hydroxy-dopamine induced degeneration of central monoamine neurons
-
UNGERSTEDT, U. 1968. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5: 107-110.
-
(1968)
Eur. J. Pharmacol.
, vol.5
, pp. 107-110
-
-
Ungerstedt, U.1
-
51
-
-
0014731101
-
Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain
-
URETSKY, N.J. & L.L. IVERSEN. 1970. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J. Neurochem. 17: 269-278.
-
(1970)
J. Neurochem.
, vol.17
, pp. 269-278
-
-
Uretsky, N.J.1
Iversen, L.L.2
-
52
-
-
0027497409
-
Parkinson's disease and increased iron in substantia nigra zona compacta
-
YOUDIM, M.B.H., D. BEN-SHACHAR & P. RIEDERER. 1993. Parkinson's disease and increased iron in substantia nigra zona compacta. Mov. Disord. 8: 1-12.
-
(1993)
Mov. Disord.
, vol.8
, pp. 1-12
-
-
Youdim, M.B.H.1
Ben-Shachar, D.2
Riederer, P.3
-
53
-
-
0032765888
-
Iron accumulation in the substantia nigra in rats visualized by ultrasound
-
BERG, D. et al. 1999. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25: 901-904.
-
(1999)
Ultrasound Med. Biol.
, vol.25
, pp. 901-904
-
-
Berg, D.1
-
54
-
-
0034776216
-
Brain iron pathways and their relevance to Parkinson's disease
-
BERG, D. et al. 2001. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79: 225-236.
-
(2001)
J. Neurochem.
, vol.79
, pp. 225-236
-
-
Berg, D.1
-
55
-
-
0027497409
-
The possible role of iron in the etiopathology of Parkinson's disease
-
YOUDIM, M.B., D. BEN-SHACHAR & P. RIEDERER. 1993. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8: 1-12.
-
(1993)
Mov. Disord.
, vol.8
, pp. 1-12
-
-
Youdim, M.B.1
Ben-Shachar, D.2
Riederer, P.3
-
56
-
-
0033373789
-
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration: Prospects for neuroprotection in Parkinson's disease with iron chelators
-
YOUDIM, M.B.H., E. GRUNBLATT & S. MANDEL. 1999. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration: prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. N.Y. Acad. Sci. 890: 7-25.
-
(1999)
Ann. N.Y. Acad. Sci.
, vol.890
, pp. 7-25
-
-
Youdim, M.B.H.1
Grunblatt, E.2
Mandel, S.3
-
57
-
-
0035474950
-
Recent advances in disorders of iron metabolism: Mutations, mechanisms, and modifiers
-
ROY, C.N. & N.C. ANDREWS. 2001. Recent advances in disorders of iron metabolism: mutations, mechanisms, and modifiers. Hum. Mol. Genet. 10: 2181-2186.
-
(2001)
Hum. Mol. Genet.
, vol.10
, pp. 2181-2186
-
-
Roy, C.N.1
Andrews, N.C.2
-
58
-
-
0035095564
-
Brain iron transport and neurodegeneration
-
QIAN, Z.M. & X. SHEN. 2001. Brain iron transport and neurodegeneration. Trends Mol. Med. 7: 103-108.
-
(2001)
Trends Mol. Med.
, vol.7
, pp. 103-108
-
-
Qian, Z.M.1
Shen, X.2
-
59
-
-
0030891276
-
The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders
-
GASSEN, M. & M.B. YOUDIM. 1997. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 80: 159-166.
-
(1997)
Pharmacol. Toxicol.
, vol.80
, pp. 159-166
-
-
Gassen, M.1
Youdim, M.B.2
-
60
-
-
0343550312
-
Apomorphine protects against MPTP-induced neurotoxicity in mice
-
GRUNBLATT, E. et al. 1999. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14: 612-618.
-
(1999)
Mov. Disord.
, vol.14
, pp. 612-618
-
-
Grunblatt, E.1
-
61
-
-
0025224512
-
Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions
-
SALAMONE, J.D., M.J. ZIGMOND & E.M. STRICKER. 1990. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience 39: 17-24.
-
(1990)
Neuroscience
, vol.39
, pp. 17-24
-
-
Salamone, J.D.1
Zigmond, M.J.2
Stricker, E.M.3
-
62
-
-
0018858892
-
Supersensitivity after intraventricular 6-hydroxydopamine: Relation to dopamine depletion
-
ZIGMOND, M.J. & E.M. STRICKER. 1980. Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion. Experientia 36: 436-438.
-
(1980)
Experientia
, vol.36
, pp. 436-438
-
-
Zigmond, M.J.1
Stricker, E.M.2
-
63
-
-
0018854896
-
Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine
-
ACHESON, A.L., M.J. ZIGMOND & E.M. STRICKER. 1980. Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricular injections of 6-hydroxydopamine. Science 207: 537-540.
-
(1980)
Science
, vol.207
, pp. 537-540
-
-
Acheson, A.L.1
Zigmond, M.J.2
Stricker, E.M.3
-
64
-
-
0038322479
-
cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells
-
WEINREB, O., S. MANDEL & M.B.H. YOUDIM. 2003. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J. 17: 935-937.
-
(2003)
FASEB J.
, vol.17
, pp. 935-937
-
-
Weinreb, O.1
Mandel, S.2
Youdim, M.B.H.3
-
65
-
-
0027351360
-
The neurotoxicity of iron and nitric oxide: Relevance to the etiology of Parkinson's disease
-
YOUDIM, M.B.H. et al. 1993. The neurotoxicity of iron and nitric oxide: relevance to the etiology of Parkinson's disease. Adv. Neurol. 60: 259-266.
-
(1993)
Adv. Neurol.
, vol.60
, pp. 259-266
-
-
Youdim, M.B.H.1
-
66
-
-
0025640845
-
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
-
SCHAPIRA, A.H. et al. 2003. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55: 2142-2145.
-
(2003)
J. Neurochem.
, vol.55
, pp. 2142-2145
-
-
Schapira, A.H.1
-
67
-
-
0035233083
-
Causes of neuronal death in Parkinson's disease
-
SCHAPIRA, A.H. 2001. Causes of neuronal death in Parkinson's disease. Adv. Neurol. 86: 155-162.
-
(2001)
Adv. Neurol.
, vol.86
, pp. 155-162
-
-
Schapira, A.H.1
-
68
-
-
0029969350
-
Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine
-
GLINKA, Y., K.F. TIPTON & M.B. YOUDIM. 1996. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J. Neurochem. 66: 2004-2010.
-
(1996)
J. Neurochem.
, vol.66
, pp. 2004-2010
-
-
Glinka, Y.1
Tipton, K.F.2
Youdim, M.B.3
-
69
-
-
0032511134
-
Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine
-
GLINKA, Y., K.F. TIPTON & M.B.H. YOUDIM. 1998. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol. 351: 121-129.
-
(1998)
Eur. J. Pharmacol.
, vol.351
, pp. 121-129
-
-
Glinka, Y.1
Tipton, K.F.2
Youdim, M.B.H.3
-
70
-
-
0028918841
-
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine
-
GLINKA, Y.Y. & M.B. YOUDIM. 1995. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292: 329-332.
-
(1995)
Eur. J. Pharmacol.
, vol.292
, pp. 329-332
-
-
Glinka, Y.Y.1
Youdim, M.B.2
-
71
-
-
0023179660
-
Inhibition of NADH oxidation by pyridine derivatives
-
RAMSAY, R.R. et al. 1987. Inhibition of NADH oxidation by pyridine derivatives. Biochem. Biophys. Res. Commun. 1: 53-60.
-
(1987)
Biochem. Biophys. Res. Commun.
, vol.1
, pp. 53-60
-
-
Ramsay, R.R.1
-
72
-
-
0031589740
-
Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors
-
SEATON, T.A., J.M. COOPER & A.H. SCHAPIRA. 1997. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777: 110-118.
-
(1997)
Brain Res.
, vol.777
, pp. 110-118
-
-
Seaton, T.A.1
Cooper, J.M.2
Schapira, A.H.3
-
73
-
-
0037378023
-
Neuroinflammatory processes in Parkinson's disease
-
HUNOT, S. & E.C. HIRSCH. 2003. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. Suppl. 3: S49-S58.
-
(2003)
Ann. Neurol. Suppl.
, vol.3
-
-
Hunot, S.1
Hirsch, E.C.2
-
74
-
-
0030842085
-
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease
-
HUNOT, S. et al. 1997. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 94: 7531-7536.
-
(1997)
Proc. Natl. Acad. Sci. USA
, vol.94
, pp. 7531-7536
-
-
Hunot, S.1
-
75
-
-
1642555537
-
Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases
-
SHOHAM, S. & M.B.H. YOUDIM. 2000. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell. Mol. Biol. 46: 743-760.
-
(2000)
Cell. Mol. Biol.
, vol.46
, pp. 743-760
-
-
Shoham, S.1
Youdim, M.B.H.2
-
76
-
-
0036145435
-
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures
-
LEVITES, Y. et al. 2002. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63: 21-29.
-
(2002)
Biochem. Pharmacol.
, vol.63
, pp. 21-29
-
-
Levites, Y.1
-
77
-
-
0030858597
-
Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages
-
LIN, M. et al. 1997. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am. J. Physiol. 272: G1355-G1364.
-
(1997)
Am. J. Physiol.
, vol.272
-
-
Lin, M.1
-
78
-
-
1542537139
-
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats
-
In press
-
BEN-SHACHAR, D. et al. 2003. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. J. Neurochem. In press.
-
(2003)
J. Neurochem.
-
-
Ben-Shachar, D.1
-
79
-
-
0037097199
-
Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain
-
SIDDAPPA, A.J. et al. 2002. Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain. J. Neurosci. Res. 68: 761-775.
-
(2002)
J. Neurosci. Res.
, vol.68
, pp. 761-775
-
-
Siddappa, A.J.1
-
80
-
-
0033826764
-
Iron regulatory proteins and the molecular control of mammalian iron metabolism
-
EISENSTEIN, R.S. 2000. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20: 627-662.
-
(2000)
Annu. Rev. Nutr.
, vol.20
, pp. 627-662
-
-
Eisenstein, R.S.1
-
81
-
-
0032746973
-
Control of transferrin receptor expression via nitric oxide-mediated modulation of iron-regulatory protein 2
-
KIM, S. & P. PONKA. 1999. Control of transferrin receptor expression via nitric oxide-mediated modulation of iron-regulatory protein 2. J. Biol. Chem. 274: 33035-33042.
-
(1999)
J. Biol. Chem.
, vol.274
, pp. 33035-33042
-
-
Kim, S.1
Ponka, P.2
-
82
-
-
0035138456
-
Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice
-
LAVAUTE, T. et al. 2001. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27: 209-214.
-
(2001)
Nat. Genet.
, vol.27
, pp. 209-214
-
-
LaVaute, T.1
-
83
-
-
0024434025
-
The putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior
-
discussion, pp. 615-617
-
YOUDIM, M.B.H., D. BEN-SHACHAR & S. YEHUDA. 1989. The putative biological mechanisms of the effect of iron deficiency on brain biochemistry and behavior. Am. J. Clin. Nutr. 50: 607-615 (discussion, pp. 615-617).
-
(1989)
Am. J. Clin. Nutr.
, vol.50
, pp. 607-615
-
-
Youdim, M.B.H.1
Ben-Shachar, D.2
Yehuda, S.3
-
84
-
-
0141940629
-
What have we learnt from cDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease
-
(a) YOUDIM, M.B.H. 2003. What have we learnt from cDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease. J. Neural Transm. Suppl. 65: 73-88;
-
(2003)
J. Neural Transm. Suppl.
, vol.65
, pp. 73-88
-
-
Youdim, M.B.H.1
-
85
-
-
1842621154
-
Iron and alpha-synuclein in the substantia nigra of MPTP treated mice: Effects of neuroprotective drugs R-apomorphine and green tea polyphenol, epigallocatechin-3-gallate
-
In press
-
(b) MANDEL, S., G. MAOR & M.B.H. YOUDIM. 2004. Iron and alpha-synuclein in the substantia nigra of MPTP treated mice: effects of neuroprotective drugs R-apomorphine and green tea polyphenol, epigallocatechin-3-gallate. J. Mol. Neurosci. In press.
-
(2004)
J. Mol. Neurosci.
-
-
Mandel, S.1
Maor, G.2
Youdim, M.B.H.3
-
86
-
-
0037013194
-
Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein
-
GOLTS, N. et al. 2002. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277: 16116-16123.
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 16116-16123
-
-
Golts, N.1
-
87
-
-
0034663039
-
The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity
-
OSTREROVA-GOLTS, N. et al. 2000. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20: 6048-6054.
-
(2000)
J. Neurosci.
, vol.20
, pp. 6048-6054
-
-
Ostrerova-Golts, N.1
-
88
-
-
0026475580
-
Iron accumulation in the rat basal ganglia after excitatory amino acid injections - Dissociation from neuronal loss
-
SHOHAM, S., E. WERTMAN & R.P. EBSTEIN. 1992. Iron accumulation in the rat basal ganglia after excitatory amino acid injections - dissociation from neuronal loss. Exp. Neurol. 118: 227-241.
-
(1992)
Exp. Neurol.
, vol.118
, pp. 227-241
-
-
Shoham, S.1
Wertman, E.2
Ebstein, R.P.3
-
89
-
-
0002404319
-
Brain iron: Function and dysfunction in relation to cognitive processes
-
Libbey. London
-
SHOHAM, S. et al. 1996. Brain iron: function and dysfunction in relation to cognitive processes. In Iron Nutrition in Health and Disease. Libbey. London.
-
(1996)
Iron Nutrition in Health and Disease
-
-
Shoham, S.1
-
90
-
-
0345714885
-
Iron misregulation in the brain: A primary cause of neurodegenerative disorders
-
KE, Y. & Z. MING QIAN. 2003. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2: 246-253.
-
(2003)
Lancet Neurol.
, vol.2
, pp. 246-253
-
-
Ke, Y.1
Ming Qian, Z.2
-
91
-
-
1842516707
-
Effect of dietary iron on motor behaviour and neuronal death in an experimental model of parkinsonism
-
In press
-
LEVENSON, C.W. et al. 2003. Effect of dietary iron on motor behaviour and neuronal death in an experimental model of parkinsonism. J. Am. Aging Assoc. In press.
-
(2003)
J. Am. Aging Assoc.
-
-
Levenson, C.W.1
-
92
-
-
0036113819
-
The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications
-
PERRY, G. et al. 2002. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16: 339-352.
-
(2002)
CNS Drugs
, vol.16
, pp. 339-352
-
-
Perry, G.1
|